•Childhood obesity linked to higher astigmatism risk•FDA clears Opus Genetics' IND for RDH12-LCA gene therapy•Physical activity lowers risk for cataract development•Euclid Vision launches cloud-based ortho-k lens fitting platform•Rayner partners with Promptly to integrate Eyejourney into US clinic software •Childhood obesity linked to higher astigmatism risk•FDA clears Opus Genetics' IND for RDH12-LCA gene therapy•Physical activity lowers risk for cataract development•Euclid Vision launches cloud-based ortho-k lens fitting platform•Rayner partners with Promptly to integrate Eyejourney into US clinic software
HEADLINES
FEATURED
Lucamzi (ranibizumab-blrz) is expected to launch in 2027 as the latest intravitreal injection with its reference biologic’s same five retinal indications.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
